Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference

PR Newswire December 28, 2017

United Therapeutics Announces Additional Six Months Of Regulatory Exclusivity For Adcirca®

PR Newswire November 20, 2017

Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and Depomed

PR Newswire November 15, 2017

SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit

GlobeNewswire November 14, 2017

United Therapeutics Corporation to Host Earnings Call

Accesswire October 25, 2017

United Therapeutics Corporation Reports Third Quarter 2017 Financial Results

PR Newswire October 25, 2017

Earnings Scheduled For October 25, 2017

Benzinga.com  October 25, 2017

United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System

PR Newswire October 23, 2017

United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017

PR Newswire October 19, 2017

Technical Snapshots for These Drug Makers Stocks -- SciClone Pharma, Synergy Pharma, Novo Nordisk, and United Therapeutics

PR Newswire October 17, 2017

Martine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds

PR Newswire September 19, 2017

Daily Technical Summary Reports on Healthcare Stocks -- Shire, Aerie Pharma, Heron Therapeutics, and United Therapeutics

PR Newswire September 11, 2017

22 Biggest Mid-Day Losers For Friday

Benzinga.com  September 8, 2017

United Therapeutics Announces FREEDOM-EV Study Of Orenitram® To Continue As Planned Following Interim Analysis

PR Newswire September 7, 2017

Celularity, Inc., Accelerates Breakthrough Placental Discovery & Therapeutic Platform

Canada NewsWire August 21, 2017

United Therapeutics Corporation To Present At 2017 Wedbush PacGrow Healthcare Conference

PR Newswire August 9, 2017

20 Biggest Mid-Day Gainers For Friday

Benzinga.com  August 4, 2017

28 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  August 4, 2017

Robbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of Shareholders

Business Wire August 3, 2017

INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Wells Fargo & Company Investors

Business Wire August 2, 2017